Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC
Not Applicable
- Conditions
- ALK-positive non-small cell lung cancer
- Registration Number
- JPRN-UMIN000035180
- Lead Sponsor
- iigata University
- Brief Summary
There was no difference in PFS or OS by serum biomarkers, but there was a trend toward longer PFS in patients with some biomarker positivity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
According to NLCTG1501
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method